MAGNUSSON ADVISED ON MAJORITY INVESTMENT IN AZANTA
A syndicate of investors included current shareholders and new shareholders of Azanta. The transaction was successfully completed on 1 October 2015. Magnusson’s team encompassed partner Søren Brinkmann and associate Sebastian Rungby.
Azanta is a privately owned specialty pharma company primarily operating within oncology, women's health and addiction medicine. Azanta seeks to be an international market leader within certain specialty pharma product categories, employing innovative repositioning and drug formulation strategies. Azanta currently markets (or makes available under special authorization) a portfolio of specialty pharmaceutical products, including Nimoral™, a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy and Angusta® for labour induction.
For more information please go to: http://www.azanta.com/
MAGNUSSON BOLSTERS ITS TURKU OFFICE IN FINLAND
The international law firm Magnusson has appointed Attorney-at-law Jussi Rintanen as a corporate partner, effective as of 1st January 2019.read more
Magnusson Lithuania continues developing its competences with two new partners in the team
The law firm meets 2019 by further strengthening its team as its two long-time associates Eglė Akelė and Dalia Stakvilevičiūtė make partners of the firm from 1 January.read more
MAGNUSSON ORGANIZED ITS ANNUAL SLUSH SIDE EVENT AT HARD ROCK CAFÉ IN HELSINKI ON 3 DEC 2018
We had 15 guest speakers, who had the opportunity to present their companies and innovative business ideas.read more
MAGNUSSON LITHUANIA ADDING NEW PARTNERS TO THE TEAM
As Magnusson Lithuania marks its 20th anniversary this year, we close this period with professional achievements of our team members: associates Rūta Didikė and Eligijus Vinckus become partners of the firm.read more